Moxifloxacin Sanovel (Moxifloxacin)

Moxifloxacin is a fluoroquinolone antibacterial indicated for several acute bacterial infections affecting the respiratory, skin and intra‑abdominal systems.

• Community-acquired pneumonia: eradicates the causative pathogens, leading to clinical improvement and resolution of pulmonary infiltrates.
• Acute bacterial sinusitis: reduces sinus inflammation by eliminating the infecting organisms and relieving congestion.
• Acute bacterial exacerbation of chronic bronchitis: controls bacterial overgrowth, decreasing sputum production and dyspnea.
• Skin and skin structure infections: treats complicated cellulitis and wound infections by targeting susceptible bacteria.
• Complicated intra-abdominal infections: provides broad‑spectrum coverage for mixed aerobic and anaerobic organisms in the abdominal cavity.

• Moxifloxacin exerts its antibacterial activity by binding to bacterial DNA gyrase (topoisomerase II) and topoisomerase IV. This inhibition prevents the supercoiling and relaxation of DNA required for replication and transcription, leading to bacterial cell death. The dual targeting enhances potency against both Gram‑negative and Gram‑positive organisms, including atypical respiratory pathogens.

Moxifloxacin may be associated with a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Diarrhea: loose stools, occasionally watery.
• Headache: transient cranial discomfort.
• Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects

• Tendon rupture: sudden pain and loss of function, especially in the Achilles.
• QT interval prolongation: may predispose to cardiac arrhythmias.
• Severe allergic reactions: rash, angioedema, or anaphylaxis.
• Clostridioides difficile colitis: severe diarrhea due to intestinal flora disruption.

Prior to prescribing Moxifloxacin, clinicians should evaluate patient‑specific factors and follow safety recommendations.

• Assess renal function: dose adjustment may be required in impaired clearance.
• Monitor cardiac status: avoid in patients with known QT prolongation or electrolyte disturbances.
• Review concomitant medications: potential for drug‑drug interactions, especially with anticoagulants.
• Caution in elderly: increased risk of tendon injury and central nervous system effects.
• Avoid in patients with known hypersensitivity to fluoroquinolones.
• Store below 25°C: keep in the original pack, protect from moisture.

Moxifloxacin can alter the pharmacokinetics or pharmacodynamics of several co‑administered agents.

Major Interactions (Avoid)

• Antacids containing magnesium or aluminum: reduce oral absorption of the drug.
• Warfarin: may increase anticoagulant effect and bleeding risk.
• Corticosteroids: heightened risk of tendon rupture when combined.
• Theophylline: increased plasma concentrations leading to toxicity.

Moderate Interactions (Monitor Closely)

• NSAIDs: additive risk of central nervous system stimulation.
• Diabetic agents (e.g., insulin, sulfonylureas): possible hypoglycaemia.
• Cyclosporine: may increase moxifloxacin levels.
• Oral contraceptives: potential reduction in efficacy.